---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-020152"
form_type: "8-K"
ticker: "NORD"
cik: "0001011060"
company_name: "Nordicus Partners Corp"
filed_at: "2024-05-16T23:59:59+00:00"
generated_at: "2026-06-01T18:26:36.948993+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Nordicus acquires 95% of Orocidin A/S for $38M in stock, enters periodontitis market

## Summary
- Acquired 525,597 Orocidin shares (95% stake) from 11 shareholders for 38M restricted common shares.
- Consideration valued at $38M in an all-stock transaction; closed May 13, 2024.
- Nordicus CEO Henrik Rouf and Director Henrik Keller join Orocidin's board of directors.
- Orocidin is a clinical-stage biopharma developing QR-01 for periodontitis; global market estimated >$1.3B by 2029.

## SEC filing metadata
- accession: 0001493152-24-020152
- form_type: 8-K
- ticker: NORD
- cik: 0001011060
- company_name: Nordicus Partners Corp
- filed_at: 2024-05-16T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 2.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1011060/000149315224020152/0001493152-24-020152-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1011060/000149315224020152/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-020152
- JSON: https://secwatch.observer/filing/0001493152-24-020152.json
- Plain text: https://secwatch.observer/filing/0001493152-24-020152.txt

## Key facts
- M&A Transactions
  Nordicus Partners Corp completed an acquisition involving certain shareholders of Orocidin A/S (closed 2024-05-13).
  - Action: acquisition
  - Counterparty: certain shareholders of Orocidin A/S
  - Closing: 2024-05-13
  source text: the Company acquired the Orocidin Shares pursuant to the Agreement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1011060/000149315224020152/0001493152-24-020152-index.htm
- Material Agreements
  Nordicus Partners Corp entered into Stock Purchase and Sale Agreement with certain shareholders of Orocidin A/S (effective 2024-05-13).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: certain shareholders of Orocidin A/S
  - Effective: 2024-05-13
  source text: On May 13, 2024, Nordicus Partners Corporation (the “Company”) and certain shareholders (the “Sellers”) of Orocidin A/S, a Danish stock corporation (“Orocidin”) entered into a Stock Purchase and Sale Agreement (the “Agreement”), under which the Sellers sold to the Company 525,597 shares of the capital stock of Orocidin (the “Orocidin Shares”), representing 95.0% of Orocidin’s outstanding shares of capital stock.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1011060/000149315224020152/0001493152-24-020152-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.